Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 6 Leukemia, Myeloid, Acute 3 Neutropenia 2 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myelomonocytic, Chronic 1 Congenital Abnormalities 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 153 Dexamethasone 140 Rituximab 83 fludarabine 79 Cytarabine 69 Lenalidomide 68 Bortezomib 64 fludarabine phosphate 62 Gemcitabine 62 venetoclax 55 Etoposide 53 pembrolizumab 52 pomalidomide 49 Paclitaxel 48 Cisplatin 47 Carboplatin 47 Peripheral Blood Stem Cell Transplantation 46 Filgrastim 40 Radiotherapy 39 Calcium Dobesilate 36 Busulfan 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 29 Vincristine 28 Temozolomide 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × Amsacrine × Clear all

NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡